Novavax Posts Light Q2 Revenue but Lifts FY26 Outlook, Flags COVID-Flu Combo Trial Progress

What happened

Novavax reported second-quarter revenue of just $57 million, revealing the ongoing collapse of direct Nuvaxovid sales and lumpy partner contributions, yet the company raised its full-year 2026 revenue framework and improved its combined R&D and SG&A expense guidance by $10 million at the midpoint. Sanofi confirmed it is in advanced discussions with regulators regarding the timing of its Phase 3 COVID-19-Influenza combination (CIC) trial, aiming for a first-mover position, while completion of the manufacturing technology transfer to Sanofi is expected in mid-2027, triggering a $75 million milestone payment. Multiple partner-led Matrix-M experiments are underway across infectious disease and oncology targets, and Novavax remains on track to advance its C. difficile vaccine program into the clinic as early as 2027. The raised guidance and expense control signal that management expects a stronger second half driven by seasonal supply sales to Sanofi and milestone recognition, even as Q2’s top-line weakness underscores the model’s dependence on partner-controlled revenue. The CIC regulatory discussions advance a key bull-case catalyst, but the lack of an actual Phase 3 start and the mid-2027 tech-transfer timeline keep the investment story anchored to execution milestones over the next 12–18 months.

Implication

The $57 million Q2 revenue print highlights the severity of the post-COVID cliff, but management’s decision to raise full-year guidance on expected supply sales and milestone payments suggests the partnership model is gaining traction. Sanofi’s confirmation of advanced talks for the COVID-flu combination trial is a concrete step toward the $125 million Phase 3 milestone, which, if triggered, would validate a key pillar of the bull case. Meanwhile, the mid-2027 tech-transfer completion target appears on track, and expense discipline is improving, offering a path to narrowed losses. However, investors remain at the mercy of partner timelines, and until royalties replace transition revenue, NVAX’s cash flow will remain lumpy and unpredictable.

Thesis delta

Q2’s anemic revenue confirms the transition away from direct sales remains painful, but the raised guidance and Sanofi’s CIC trial advancement modestly increase confidence that partner economics are developing. The thesis still hinges on revenue quality shifting from reimbursements to royalties and milestones; no rating change is warranted until a major milestone is actually recognized.